Ametop Compared to Ametop With Pain Ease Spray
Launched by UNIVERSITY OF BRITISH COLUMBIA · Nov 19, 2018
Trial Information
Current as of June 15, 2025
Unknown status
Keywords
ClinConnect Summary
Purpose:
The aim of this study is to assess the effectiveness of Pain Ease® spray, used as an adjunct to Ametop Gel™.
Hypothesis:
The investigators hypothesize that using Pain Ease® spray as an adjunct to the standard use of Ametop Gel™ will increase the number of pain free venipunctures from 30% to 50% or more.
Objectives:
Primary Objective
1. To determine if using Pain Ease® spray as an adjunct to Ametop Gel™ will increase the number of pain free venipunctures Secondary Objectives
2. To document the side effects of Pain Ease® spray and Ametop Gel™
3. To document the number of attemp...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA I \& II
- • Elective day case procedure requiring an IV
- Exclusion Criteria:
- • Planned IV insertion after inhalation induction
- • Developmental delay or inability to interpret the Revised Faces Pain Scale (FPS-R)10
- • Ametop Gel™ application \< 30 minutes before estimated IV start at time of screening
- • Allergies to any of the components in Ametop Gel™, Pain Ease® spray, or adhesives
- • Patients receiving sedative pre-medication
- • Severe Needle phobia
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Stephan Malherbe, FRCA
Principal Investigator
BC Children's Hospital, Department of Anesthesia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials